|
Werbie, LLC is a startup committed to women’s health, nutrition, and wellness. Founder: Catherine Jones Source: Relevant Health |
|
|
Neopenda is a simple, affordable neonatal vital signs monitor integrated into a baby hat. Founder: Sona Shah Source: Relevant Health |
|
|
Gastro Girl is an online health health coaching platform specifically designed to help individuals who struggle with common gastrointestinal (GI) symptoms such as gas, bloating, constipation, diarrhea and chronic abdominal pain–heal their digestive system and improve their overall health and wellness. Founder: Jacqueline Gualine BHI Lead Contact: Judy Costello Source: Relevant Health |
|
|
Automated speech and face muscle trainer for children. Join our Speech Therapist pilot studies. Founder: Ilze Zaharane BHI Lead Contact: Judy Costello Source: Relevant Health |
|
|
AgeWell Biometrics improves senior care and quality of life by providing objective, precise and predictive fall risk assessment. Founder: Joshua Wies BHI Lead Contact: Judy Costello Source: Relevant Health |
|
|
A polymer-based neoantigen company from JHU, NIH, Oxford and Prague polymer institute Founder: Geoffrey Lynn Source: NIH/Oxford/Prague |
Efforts to fight antibiotic-resistant infections — often dubbed superbugs — typically involve strategies of curbing overuse of the antibiotics we already have or finding alternatives.
But what if those pesky superbug infections could simply be prevented in the first place? It’s the strategy Gaithersburg-based MedImmune is taking with two of its vaccine candidates aimed at bacterial infections.
Tuesday November 3, 2 pm ET
Congratulations – you just got a Notice of Award for an NIH SBIR/STTR grant – now what? How do you actually use those funds? This educational webinar about the Payment Management System will help you figure that out, with plenty of time for Q&A. This is highly recommended for new awardees.
Learn more about the Payment Management System: http://bit.ly/HHSpms
Presenter: Nicole Dunning Chief, University and Non-Profit Payment Section Payment Management Services Program Support Center U.S. Department of Health and Human Services
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that the first healthy participant has been dosed with a subcutaneous (SC) formulation of rivipansel in a Phase 1, single ascending-dose clinical study to evaluate its safety, tolerability and pharmacokinetics. Rivipansel (GMI-1070) is an investigational compound being studied as a potential therapy for the treatment of vaso-occlusive crisis (VOC) in sickle cell disease and is being developed by Pfizer Inc. under a worldwide licensing agreement the two companies entered into in 2011.
The SC formulation of rivipansel utilizes Enhanze™ Technology, licensed by Pfizer from Halozyme Therapeutics, Inc. This technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies components of the extracellular matrix in order to aid in the dispersion and absorption of other SC injected therapeutic drugs.
Maybe healthcare is thinking about data from wearable devices in all the wrong ways.
Speaking Thursday at the 12th annual Connected Health Symposium in Boston, Dr. Robert Pearl, CEO of Kaiser Permanente‘s Permanente Medical Group, said that, from a physician’s perspective, Fitbits and other fitness trackers are good for one thing: “December.” In other words, they make great Christmas gifts, but don’t serve much purpose in medical practice.